New Number of Shares and Votes in Senzime AB (publ)
Senzime AB has announced changes in its share structure during October 2024. The company completed a directed share issue of 12,769,000 shares, increasing the total number of shares from 119,705,523 to 132,474,523. The share capital has risen to SEK 16,559,315.375 from SEK 14,963,190.375. An additional 1,104,000 shares from another directed share issue are pending registration following approval at the extraordinary general meeting on October 23, 2024. The company currently holds no treasury shares.
Senzime AB ha annunciato modifiche nella sua struttura azionaria durante ottobre 2024. L'azienda ha completato un'emissione diretta di 12.769.000 azioni, aumentando il numero totale di azioni da 119.705.523 a 132.474.523. Il capitale azionario è salito a SEK 16.559.315,375 da SEK 14.963.190,375. Sono in attesa di registrazione ulteriori 1.104.000 azioni provenienti da un'altra emissione diretta, dopo l'approvazione dell'assemblea generale straordinaria del 23 ottobre 2024. Attualmente, l'azienda non detiene azioni proprie.
Senzime AB ha anunciado cambios en su estructura de acciones durante octubre de 2024. La empresa completó una emisión de acciones dirigida de 12.769.000 acciones, aumentando el número total de acciones de 119.705.523 a 132.474.523. El capital social ha aumentado a SEK 16.559.315,375 desde SEK 14.963.190,375. Se están pendientes de registro 1.104.000 acciones de otra emisión de acciones dirigida, tras la aprobación en la junta general extraordinaria el 23 de octubre de 2024. Actualmente, la empresa no posee acciones en tesorería.
Senzime AB는 2024년 10월에 주식 구조 변경을 발표했습니다. 이 회사는 12,769,000주의 유도 주식 발행을 완료하여 총 주식 수를 119,705,523주에서 132,474,523주로 늘렸습니다. 자본금은 SEK 14,963,190.375에서 SEK 16,559,315.375로 증가했습니다. 2024년 10월 23일 특별 총회에서 승인된 후 다른 유도 주식 발행에서 1,104,000주가 등록 대기 중입니다. 현재 이 회사는 자사주를 보유하고 있지 않습니다.
Senzime AB a annoncé des changements dans sa structure d'actions en octobre 2024. L'entreprise a complété une émission d'actions dirigée de 12.769.000 actions, portant le nombre total d'actions de 119.705.523 à 132.474.523. Le capital social a augmenté de SEK 14.963.190,375 à SEK 16.559.315,375. En outre, 1.104.000 actions d'une autre émission d'actions dirigée sont en attente d'enregistrement après approbation lors de l'assemblée générale extraordinaire le 23 octobre 2024. Actuellement, l'entreprise ne détient aucune action propre.
Senzime AB hat im Oktober 2024 Änderungen in seiner Aktienstruktur bekannt gegeben. Das Unternehmen hat eine gezielte Aktienemission von 12.769.000 Aktien abgeschlossen, wodurch sich die Gesamtanzahl der Aktien von 119.705.523 auf 132.474.523 erhöht hat. Das Aktienkapital ist von SEK 14.963.190,375 auf SEK 16.559.315,375 gestiegen. Zusätzlich sind 1.104.000 Aktien aus einer weiteren gezielten Aktienemission zur Registrierung ausstehend, nachdem sie auf der außerordentlichen Hauptversammlung am 23. Oktober 2024 genehmigt wurden. Das Unternehmen hält derzeit keine eigenen Aktien.
- None.
- Share dilution through issuance of 12,769,000 new shares
- Additional dilution pending with 1,104,000 shares awaiting registration
UPPSALA, SWEDEN / ACCESSWIRE / October 31, 2024 / The number of shares and votes in Senzime AB (publ) (STO:SEZI)(OTCQX:SNZZF) ("Senzime") has increased during October due to the directed share issue of 12,769,000 shares resolved by the board of directors on 27 September 2024, based on the authorization granted by the annual general meeting on 16 May 2024. Please note that the 1,104,000 shares included in the other directed share issue resolved by the board on the same day, subject to subsequent approval by the extraordinary general meeting on 23 October 2024, have not yet been registered, and therefore are not included in this information.
As of 31 October 2024, the total number of shares in Senzime amounts to 132,474,523 shares (previously 119,705,523 shares), with one vote each. The share capital amounts to SEK 16,559,315.375 (previously SEK 14,963,190.375).
As of 31 October 2024, Senzime holds no treasury shares.
For further information, please contact:
Philip Siberg, CEO of Senzime AB
Phone: +46 (0) 707 90 67 34, e-mail: philip.siberg@senzime.com
Slavoljub Grujicic, CFO
Phone: +46 (0) 76 306 60 11, e-mail: slavoljub.grujicic@senzime.com
About Senzime
Senzime develops CE- and FDA-cleared precision-based patient monitoring solutions to safeguard patients during anesthesia and recovery. Senzime's TetraGraph® and ExSpiron® 2Xi systems are powered by proprietary, smart algorithms to monitor neuromuscular and respiratory function in real-time during and after surgery. The technologies are based on 40+ years of science and developed to enhance patient safety targeting over 100 million patients globally. Senzime's products are commercialized in over 30 countries including direct sales teams in US and Germany.
Established in 1999 and headquartered in Uppsala, Sweden, Senzime is backed by long-term investors and listed on the Nasdaq Stockholm Main Market (SEZI), with cross-trading on the New York OTCQX market (SNZZF). More information is available at senzime.com.
This information is information that Senzime is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2024-10-31 15:00 CET.
Attachments
New number of shares and votes in Senzime AB (publ)
SOURCE: Senzime
View the original press release on accesswire.com
FAQ
What is the new total number of shares in Senzime (SNZZF) as of October 31, 2024?
How many new shares were issued by Senzime (SNZZF) in October 2024?
What is Senzime's (SNZZF) new share capital as of October 31, 2024?
